Physician profile
Vidya R Ajaradder
NPI 1275543928
$824.30
in general payments reported to CMS, 2019-2025
24 companies · $21.71 in 2025
The $21.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $74.59 · 2022: $421 · 2023: $140 · 2024: $23.25 · 2025: $21.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $115.09 | 2022-2023 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.71 | 2019-2022 | |
| Lundbeck LLC | $66.72 | 2020-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.98 | 2022 | |
| Novo Nordisk INC | $63.56 | 2019-2022 | |
| Dexcom, INC. | $63.31 | 2022-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $45.58 | 2020-2022 | |
| Amarin Pharma, INC. | $31.50 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.06 | 2022 | |
| Daiichi Sankyo INC. | $28.02 | 2019 | |
| Abbott Laboratories | $23.25 | 2024 | Octrode |
| Otsuka America Pharmaceutical, INC. | $22.04 | 2022 | |
| Boston Scientific Corporation | $21.71 | 2025 | Solyx Sis System |
| Biohaven Pharmaceutical Holding Company LTD. | $20.53 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.49 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.35 | 2019 | |
| Exact Sciences Corporation | $16.71 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $16.59 | 2020 | |
| Neurocrine Biosciences, INC. | $15.41 | 2019 | |
| Glaxosmithkline, LLC. | $14.58 | 2022 | |
| Astellas Pharma US INC | $13.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.83 | 2020 | |
| Lilly USA, LLC | $12.67 | 2019 | |
| Pfizer INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidya Ajaradder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.